REVB

Revelation Biosciences Inc

REVB, USA

Revelation Biosciences, Inc. operates as a clinical-stage biopharmaceutical company that focuses on the development and commercialization of immune system therapeutics and diagnostics. It engages in developing therapeutic product candidates, including GEM-AKI, a potential therapy for the prevention and treatment of acute kidney injury; and GEM-CKD, a potential therapy for the prevention and treatment of chronic kidney disease. The company was formerly known as Petra Acquisition, Inc. and changed its name to Revelation Biosciences, Inc. in January 2022. Revelation Biosciences, Inc. was incorporated in 2019 and is based in San Diego, California.

https://www.revbiosciences.com

Stock Price

$0.00

0%

increase compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
REVB
stock
REVB

Growth Review: Will REVB benefit from current market trends - July 2025 Chart Watch & Detailed Earnings Play Alerts baoquankhu1.vn

Read more →
REVB
stock
REVB

Aug Drivers: Does REVB offer margin of safety - Weekly Investment Recap & Expert Approved Trade Ideas baoquankhu1.vn

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

BUY

Target Price:

$21.25

Analyst Picks

Strong Buy

0

Buy

1

Hold

0

Sell

0

Strong Sell

0

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Earnings Ratio (P/E)

-

Very High

0.01

Low ≥ 50

High ≤ 10

Price to Book Ratio (P/B)

-

Very Low

0.22

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Very Low

-17.34 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Very Low

-14.83 %

Low ≤ 2%

High ≥ 10%

Debt to Equity

-

Very High

0.17

Low ≥ 1

High ≤ 0.3

Investors

* Institutions hold a combined 0.17% of the total shares of Revelation Biosciences Inc

1.

Fidelity Extended Market Index

(0.0668%)

since

2025/07/31

2.

Tower Research Capital LLC

(0.0401%)

since

2025/03/31

3.

SBI Securities Co Ltd

(0.0273%)

since

2025/06/30

4.

Royal Bank of Canada

(0.0265%)

since

2025/03/31

5.

UBS Group AG

(0.0068%)

since

2025/03/31

6.

Bank of America Corp

(0.0004%)

since

2025/03/31

7.

SSgA U.S. Total Market Index Strategy

(0.0001%)

since

2025/03/31

8.

State St US Extended Mkt Indx NL Cl C

(0.0001%)

since

2025/08/31

10.

IFP Advisors, LLC

(0%)

since

2025/06/30

11.

XTX Topco Ltd

(0%)

since

2025/03/31

12.

TWO SIGMA SECURITIES, LLC

(0%)

since

2025/03/31

13.

NT Ext Eq Mkt Indx Fd DC Lend T3

(0%)

since

2024/12/31

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

—

EPS Estimate

—

Latest Release

Date

2025-09-30

EPS Actual

-1.77

EPS Estimate

-9.6

EPS Difference

7.83

Surprise Percent

81.5625%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Strong Deep Value(9)
Defensive
Highly Defensive(7)
Dividend
Weak Dividend Profile(1.5)
Economic Moat
Some Competitive Advantage(3.8)
GARP
Not Attractive for GARP(2)
Growth
Weak Growth Prospect(0.5)
Momentum
No Momentum(2)
Net Net
Strong Net-Net(8)
Quality
Low Quality Business(2.5)
Value
Undervalued(9)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.